About Plasma membrane ascorbate-dependent reductase CYBRD1
Plasma membrane ascorbate-dependent reductase CYBRD1 (CYBRD1) is a protein
from Homo sapiens identified by UniProt accession
Q53TN4, 286 residues long.
MolForge cross-references it against 0 known binders and
142 disease associations.
Target properties
| Protein name | Plasma membrane ascorbate-dependent reductase CYBRD1 |
|---|
| UniProt accession | Q53TN4 |
|---|
| Gene | CYBRD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 286 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (142)
Diseases linked to this target (Open Targets).
- lean body mass · score 0.46
- BMI-adjusted waist-hip ratio · score 0.44
- appendicular lean mass · score 0.43
- heel bone mineral density · score 0.40
- body weight · score 0.40
- body fat distribution · score 0.37
- hereditary hemochromatosis · score 0.37
- pulse pressure measurement · score 0.37
- BMI-adjusted hip circumference · score 0.36
- fat body mass · score 0.35
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q53TN4-F1 | alphafold | PREDICTED | 86.65 | — |
Amino-acid sequence (286 residues)
MAMEGYWRFL ALLGSALLVG FLSVIFALVW VLHYREGLGW DGSALEFNWH PVLMVTGFVF IQGIAIIVYR LPWTWKCSKL LMKSIHAGLN AVAAILAIIS VVAVFENHNV NNIANMYSLH SWVGLIAVIC YLLQLLSGFS VFLLPWAPLS LRAFLMPIHV YSGIVIFGTV IATALMGLTE KLIFSLRDPA YSTFPPEGVF VNTLGLLILV FGALIFWIVT RPQWKRPKEP NSTILHPNGG TEQGARGSMP AYSGNNMDKS DSELNSEVAA RKRNLALDEA GQRSTM
Explore Plasma membrane ascorbate-dependent reductase CYBRD1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets